Chunguang Ma1, Wangrui Liu2, Aihetaimujiang Anwaier1, Wenhao Xu1, Xi Tian1, Guohai Shi1, Yuanyuan Qu3, Shiyin Wei4, Hailiang Zhang5, Dingwei Ye6. 1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical college, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. 2. Affiliated Hospital of Youjiang Medical University for Nationalities, Zhongshan 2nd Road 18, Baise, 533000, People's Republic of China. 3. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical college, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. quyy1987@163.com. 4. Affiliated Hospital of Youjiang Medical University for Nationalities, Zhongshan 2nd Road 18, Baise, 533000, People's Republic of China. yjweishiyin@163.com. 5. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical college, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. zhanghl918@163.com. 6. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical college, Fudan University, Dong'an Road 270, Shanghai, 200032, People's Republic of China. dwyelie@163.com.
Abstract
BACKGROUND: The tumor microenvironment (TME) and tertiary lymphoid structures (TLS) affect the occurrence and development of cancers. How the immune contexture interacts with the phenotype of clear cell renal cell carcinoma (ccRCC) remains unclear. METHODS: We identified and evaluated TLS clusters in ccRCC using machine learning algorithms and the 12-chemokine gene signature for TLS. Analyses for functional enrichment, DNA variation, immune cell distribution, association with independent clinicopathological features and predictive value of CXCL13 in ccRCC were performed. RESULTS: We found a prominently enrichment of the 12-chemokine gene signature for TLS in patients with ccRCC compared with other types of renal cell carcinoma. We identified a prognostic value of CCL4, CCL5, CCL8, CCL19 and CXCL13 expression in ccRCC. DNA deletion of the TLS gene signature significantly predicted poor outcome in ccRCC compared with amplification and wild-type gene signature. We established TLS clusters (C1-4) and observed distinct differences in survival, stem cell-like characteristics, immune cell distribution, response to immunotherapies and VEGF-targeted therapies among the clusters. We found that elevated CXCL13 expression significantly predicted aggressive progression and poor prognosis in 232 patients with ccRCC in a real-world validation cohort. CONCLUSION: This study described a 12-chemokine gene signature for TLS in ccRCC and established TLS clusters that reflected different TME immune status and corresponded to prognosis of ccRCC. We confirmed the dense presence of TILs aggregation and TLS in ccRCC and demonstrated an oncogenic role of CXCL13 expression of ccRCC, which help develop immunotherapies and provide novel insights on the long-term management of ccRCC.
BACKGROUND: The tumor microenvironment (TME) and tertiary lymphoid structures (TLS) affect the occurrence and development of cancers. How the immune contexture interacts with the phenotype of clear cell renal cell carcinoma (ccRCC) remains unclear. METHODS: We identified and evaluated TLS clusters in ccRCC using machine learning algorithms and the 12-chemokine gene signature for TLS. Analyses for functional enrichment, DNA variation, immune cell distribution, association with independent clinicopathological features and predictive value of CXCL13 in ccRCC were performed. RESULTS: We found a prominently enrichment of the 12-chemokine gene signature for TLS in patients with ccRCC compared with other types of renal cell carcinoma. We identified a prognostic value of CCL4, CCL5, CCL8, CCL19 and CXCL13 expression in ccRCC. DNA deletion of the TLS gene signature significantly predicted poor outcome in ccRCC compared with amplification and wild-type gene signature. We established TLS clusters (C1-4) and observed distinct differences in survival, stem cell-like characteristics, immune cell distribution, response to immunotherapies and VEGF-targeted therapies among the clusters. We found that elevated CXCL13 expression significantly predicted aggressive progression and poor prognosis in 232 patients with ccRCC in a real-world validation cohort. CONCLUSION: This study described a 12-chemokine gene signature for TLS in ccRCC and established TLS clusters that reflected different TME immune status and corresponded to prognosis of ccRCC. We confirmed the dense presence of TILs aggregation and TLS in ccRCC and demonstrated an oncogenic role of CXCL13 expression of ccRCC, which help develop immunotherapies and provide novel insights on the long-term management of ccRCC.
Authors: R Elaidi; A Harbaoui; B Beuselinck; J-C Eymard; A Bamias; E De Guillebon; C Porta; Y Vano; C Linassier; P R Debruyne; M Gross-Goupil; A Ravaud; M Aitelhaj; G Marret; S Oudard Journal: Ann Oncol Date: 2014-12-01 Impact factor: 32.976
Authors: Rita Cabrita; Martin Lauss; Adriana Sanna; Marco Donia; Mathilde Skaarup Larsen; Shamik Mitra; Iva Johansson; Bengt Phung; Katja Harbst; Johan Vallon-Christersson; Alison van Schoiack; Kristina Lövgren; Sarah Warren; Karin Jirström; Håkan Olsson; Kristian Pietras; Christian Ingvar; Karolin Isaksson; Dirk Schadendorf; Henrik Schmidt; Lars Bastholt; Ana Carneiro; Jennifer A Wargo; Inge Marie Svane; Göran Jönsson Journal: Nature Date: 2020-01-15 Impact factor: 49.962
Authors: Lisha Wang; Sean R Williamson; Mingsheng Wang; Darrell D Davidson; Shaobo Zhang; Lee Ann Baldridge; Xiang Du; Liang Cheng Journal: Mol Cancer Date: 2014-02-26 Impact factor: 27.401